Our latest deal of the week is Curaleaf Holdings £246m acquisition of Emmac Life Sciences.
Who they are
Curaleaf is a medical and wellness cannabis producer, based in the US. They specialise in the production of cannabis-based products and operate over 100 dispensaries, 23 cultivations sites and over 30 processing facilities. Emmac Life Sciences is a UK headquartered producer and supplier of medicinal cannabis products.
What we liked about this deal
Curaleaf is the industry leader in the US for cannabis-based products and they anticipate significant growth from the European CBD based products market, making Emmac an ideal acquisition.
In 2018, Curalead raised over $400m and they have been on the acquisition trail since, acquiring a number of smaller players in the industry including BlueKudu and Grassroots Cannabis.
The cannabis sector has seen a considerable amount of M&A activity in recent years with countries around the world legalising CBD for medicinal purposes and personal use, with the most significant acquisition being Jazz Pharmaceuticals acquisition of GW Pharmaceuticals which is due to complete later this year.